Market News
Recent Developments
New product approvals/launches
- In February 2022, the Ultrathin Strut Orsiro Coronary Drug-Eluting Stent (DES) by BIOTRONIK, a medical device company, set a new clinical benchmark. The final 5-year data from the BIOFLOW-V trial confirms Orsiro DES' superior safety, reaffirming Orsiro's status as the clinical benchmark for DES.
- In June 2021, QualiMed, a wholly-owned subsidiary of a Q3 Medical Devices Limited, announced that it has received CE mark approval for a dedicated percutaneous biodegradable metal alloy-based stent implant for biliary applications, the UNITY-B Percutaneous Balloon Expandable Biodegradable Biliary Stent (BEBS).
Collaboration, partnership, and agreement
- On May 30, 2023, CoSo Health, a global healthcare logistics company, announced the signing a U.S. distribution agreement with Medinol, a healthcare company dedicated to the science of cardiovascular intervention, for EluNIR, a new generation, thin-strut drug-eluting stent (DES).
- In October 2022, Cordis, a worldwide leader in the development and manufacturing of interventional cardiovascular and endovascular technologies, announced its acquisition, subject to customary closing conditions including regulatory approvals, of MedAlliance, a Switzerland-based company at the forefront of transformative drug-eluting balloons.
- In September 2022, Gentinge, a global medical technological company, announced a supply partnership with Medtronic, a medical device company, which recently received CE mark for the Radiant covered stent, the first covered stent indicated for chimney endovascular aneurysm repair (ChEVAR).
U.S.: 
U.K. : 
India : 
